In MS, serious adverse effects are more common in rituximab versus ocrelizumabSeptember 11, 2020Multiple Sclerosis
Lowering rituximab dose in patients with MS proves safe and effectiveSeptember 9, 2020Multiple Sclerosis
FDA approves Uplizna for treatment of anti-AQP4 antibody–positive NMOSDJune 15, 2020Multiple Sclerosis
FDA approves ozanimod for relapsing and secondary progressive forms of MSMarch 26, 2020Multiple Sclerosis
Serum levels of neurofilament light are increased before clinical onset of MSFebruary 6, 2020Multiple Sclerosis
